ImmunityBio is one of the more unusual biotech stories in the U.S. small-to-mid cap universe because it sits at the intersection of three narratives that rarely move in a straight line: a real commercial oncology product, a broad immunotherapy platform with ambitious expansion plans, and a regulatory history that has forced the market to constantly reassess how much execution risk should be attached to the company.

The heart of the story is ANKTIVA, also known as nogapendekin alfa inbakicept-pmln or N-803, an IL-15 receptor agonist designed to activate natural killer cells and CD8+ T cells while supporting immune memory. The first major commercial validation came in April 2024, when the FDA approved ANKTIVA in combination with Bacillus Calmette-Guérin for adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. This is not an abstract platform milestone. It is a marketed drug in a defined oncology indication, with product revenue that has moved from early launch levels into a much more visible commercial ramp.

While the data appear encouraging on one side, I am not fully satisfied with how the company communicated them.

This is not a medical issue; it is a public relations and market-positioning issue. I am the first to say that companies should not fuel unnecessary hype, especially in biotech. But when a company is publicly listed, fast, broad and complete communication is necessary, because for shareholders it is also a numbers question, not only a clinical one.

The outlook remains promising going forward, but today, no — I cannot say I am satisfied.

* I created a new page designed to bring together, in one single view, the articles that follow the story, so the content is better organized and easier to navigate.

The next step will be to update it and expand it over time.

I hope it can be useful as a quick overview.

And hopefully, next time, they won’t wait two days to release the news — especially not almost in a whisper.

Castellum Q1 2026: backlog reaches record level as the debt-free turnaround moves into execution mode

Q1 did not simply add another revenue beat to the story. It gave investors the first real post-cleanup test of whether Castellum’s 2025 contract wins are beginning to show up in reported numbers.

A full evergreen hub for POET Technologies: company story, Optical Interposer technology, AI photonics opportunity, commercial path, manufacturing ecosystem, cash position, retail sentiment, risks, and the operating milestones that matter beyond any single headline.

Good morning everyone.

Today I managed to publish the update to the DRTS page on my blog.

Since the topic came up, I also wanted to clarify one thing about the blog. Some people in another subreddit complained that there is a Google “offerwall” when opening the site.

To be honest, I don’t like ads either. But since this is not a commercial site with paid subscriptions, using an ad is one of the few ways to at least partially offset the costs of running it.

I believe placing it at the beginning of the page is the best choice, because at the moment it is the only ad on the site. Once closed, readers can continue reading without having extra ads or unnecessary elements loaded throughout the article, which also helps keep the reading experience cleaner.

I think the quality and depth of the articles are worth a few seconds of an ad.

Enjoy the read. :)

https://www.merlintrader.com/alpha-tau-stock-hub/